CARGO Therapeutics (CRGX) Director’s 25,000 Options Converted in Acquisition
Rhea-AI Filing Summary
David Charles Lubner, a director of CARGO Therapeutics, Inc. (CRGX), reported the disposition of a stock option covering 25,000 shares on 08/19/2025. The Form 4 shows the option had an exercise price of $4.35 and was reported as disposed (D), leaving 0 derivative securities beneficially owned after the transaction. The footnotes state the disposition occurred pursuant to the Agreement and Plan of Merger dated July 7, 2025, under which a tender offer completed on August 18, 2025 offered $4.379 per share in cash plus one non-transferable Contingent Value Right (CVR) per share. The filing explains that outstanding options were vested and then, if not exercised, canceled and converted into cash and CVRs consistent with the merger terms.
Positive
- Merger completed with a tender offer providing $4.379 per share plus one CVR, giving option holders a defined cash and contingent-right outcome
- Options fully vested prior to conversion, ensuring holders received the merger consideration rather than forfeiting unvested awards
Negative
- Director's derivative position reduced to zero (25,000 options reported disposed), eliminating that form of insider equity exposure
- Options were canceled and converted under merger terms, which could be less valuable than retained equity if future upside materializes
Insights
TL;DR: Director reported cancellation/disposition of 25,000 options for cash plus CVR as part of a completed merger/tender offer.
The Form 4 discloses a material insider change: a director's derivative position of 25,000 options with a $4.35 strike was reported disposed on 08/19/2025 and shows zero derivative holdings afterward. The filing explicitly ties the disposition to a Merger Agreement and a tender offer that paid $4.379 per share plus a CVR, and states options were converted/cash-settled under merger terms. For investor analysis, this is a corporate-control event that removes previously outstanding director-held options and replaces potential equity exposure with cash and contingent rights, which can affect post‑transaction ownership and incentive alignment.
TL;DR: Transaction reflects standard option treatment in an acquisition: vesting, cash settlement and issuance of CVRs per merger agreement.
The disclosure is consistent with common M&A mechanics: a merger/tender offer closed on August 18, 2025, offering $4.379 per share plus one CVR. The Form 4 shows that unexercised options became vested and were then canceled and converted into cash amounts equal to the excess of the cash offer over strike, plus CVRs per underlying share. The director’s derivative holdings were eliminated (0 remaining), indicating full contract-level treatment rather than retention of equity instruments. This is a material corporate event but follows the explicit terms disclosed rather than indicating contested or unusual treatment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
Footnotes (1)
- Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.
